ORMP
Price
$2.38
Change
-$0.00 (-0.00%)
Updated
Nov 7 closing price
Earnings call today
URGN
Price
$12.10
Change
-$0.00 (-0.00%)
Updated
Nov 7 closing price
125 days until earnings call
Ad is loading...

ORMP vs URGN

Header iconORMP vs URGN Comparison
Open Charts ORMP vs URGNBanner chart's image
Oramed Pharmaceuticals
Price$2.38
Change-$0.00 (-0.00%)
Volume$126.6K
CapitalizationN/A
UroGen Pharma
Price$12.10
Change-$0.00 (-0.00%)
Volume$304.01K
CapitalizationN/A
View a ticker or compare two or three
ORMP vs URGN Comparison Chart
Loading...
ORMP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
ORMP vs. URGN commentary
Nov 09, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ORMP is a Hold and URGN is a StrongSell.

COMPARISON
Comparison
Nov 09, 2024
Stock price -- (ORMP: $2.38 vs. URGN: $12.10)
Brand notoriety: ORMP and URGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ORMP: 141% vs. URGN: 49%
Market capitalization -- ORMP: $95.6M vs. URGN: $509.58M
ORMP [@Biotechnology] is valued at $95.6M. URGN’s [@Biotechnology] market capitalization is $509.58M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.24B to $0. The average market capitalization across the [@Biotechnology] industry is $2.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ORMP’s FA Score shows that 0 FA rating(s) are green whileURGN’s FA Score has 0 green FA rating(s).

  • ORMP’s FA Score: 0 green, 5 red.
  • URGN’s FA Score: 0 green, 5 red.
According to our system of comparison, ORMP is a better buy in the long-term than URGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ORMP’s TA Score shows that 4 TA indicator(s) are bullish while URGN’s TA Score has 4 bullish TA indicator(s).

  • ORMP’s TA Score: 4 bullish, 5 bearish.
  • URGN’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, URGN is a better buy in the short-term than ORMP.

Price Growth

ORMP (@Biotechnology) experienced а 0.00% price change this week, while URGN (@Biotechnology) price change was -1.31% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.66%. For the same industry, the average monthly price growth was +14.64%, and the average quarterly price growth was +11.72%.

Reported Earning Dates

ORMP is expected to report earnings on Feb 26, 2025.

URGN is expected to report earnings on Mar 13, 2025.

Industries' Descriptions

@Biotechnology (+3.66% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
URGN($510M) has a higher market cap than ORMP($94.2M). ORMP YTD gains are higher at: 3.030 vs. URGN (-19.333). ORMP has higher annual earnings (EBITDA): 25.5M vs. URGN (-94.89M). URGN has more cash in the bank: 241M vs. ORMP (153M). ORMP has less debt than URGN: ORMP (486K) vs URGN (98.2M). URGN has higher revenues than ORMP: URGN (85M) vs ORMP (0).
ORMPURGNORMP / URGN
Capitalization94.2M510M18%
EBITDA25.5M-94.89M-27%
Gain YTD3.030-19.333-16%
P/E Ratio4.53N/A-
Revenue085M-
Total Cash153M241M63%
Total Debt486K98.2M0%
FUNDAMENTALS RATINGS
ORMP vs URGN: Fundamental Ratings
ORMP
URGN
OUTLOOK RATING
1..100
639
VALUATION
overvalued / fair valued / undervalued
1..100
52
Fair valued
78
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
54100
PRICE GROWTH RATING
1..100
5761
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORMP's Valuation (52) in the Pharmaceuticals Other industry is in the same range as URGN (78) in the Biotechnology industry. This means that ORMP’s stock grew similarly to URGN’s over the last 12 months.

ORMP's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as URGN (100) in the Biotechnology industry. This means that ORMP’s stock grew similarly to URGN’s over the last 12 months.

ORMP's SMR Rating (54) in the Pharmaceuticals Other industry is somewhat better than the same rating for URGN (100) in the Biotechnology industry. This means that ORMP’s stock grew somewhat faster than URGN’s over the last 12 months.

ORMP's Price Growth Rating (57) in the Pharmaceuticals Other industry is in the same range as URGN (61) in the Biotechnology industry. This means that ORMP’s stock grew similarly to URGN’s over the last 12 months.

ORMP's P/E Growth Rating (99) in the Pharmaceuticals Other industry is in the same range as URGN (100) in the Biotechnology industry. This means that ORMP’s stock grew similarly to URGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ORMPURGN
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 17 days ago
83%
Bullish Trend 3 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 5 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
ORMP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EIISX15.050.23
+1.55%
Parametric International Equity I
SCICX61.020.82
+1.36%
Columbia Seligman Tech & Info C
PGRSX9.910.10
+1.02%
Principal Global Real Estate Sec R6
CLFFX19.960.08
+0.40%
Clifford Capital Partners Investor
STRBX22.87-0.27
-1.17%
Sterling Capital Behav Sm Cp Val Eq R6

ORMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with KRYS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then KRYS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORMP
1D Price
Change %
ORMP100%
+1.71%
KRYS - ORMP
48%
Loosely correlated
+1.29%
ALDX - ORMP
45%
Loosely correlated
-1.30%
BPMC - ORMP
44%
Loosely correlated
+1.76%
BTAI - ORMP
44%
Loosely correlated
-8.21%
INO - ORMP
44%
Loosely correlated
-2.65%
More

URGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, URGN has been loosely correlated with CYYNF. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if URGN jumps, then CYYNF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To URGN
1D Price
Change %
URGN100%
-1.14%
CYYNF - URGN
38%
Loosely correlated
N/A
SPRB - URGN
32%
Poorly correlated
+0.68%
ORMP - URGN
28%
Poorly correlated
+1.71%
RZLT - URGN
28%
Poorly correlated
-1.55%
GOSS - URGN
27%
Poorly correlated
-0.02%
More